期刊文献+

正常反应人群拮抗剂方案与激动剂长方案的临床特点及结局比较 被引量:2

Clinical features and outcomes of IVF-ET cycles between GnRH antagonist and GnRH agonist long protocol in normal responders:a comparison of 266 cases
下载PDF
导出
摘要 目的分析比较体外授精-胚胎移植(in vitro fertilization-embryo transfer,IVF-ET)治疗中采用促性腺激素释放激素(gonadotrophin releasing hormone,GnRH)拮抗剂方案(简称拮抗剂方案)或激动剂长方案(简称长方案)的正常反应人群IVF-ET周期的临床特点及结局。方法收集2017年1月至2019年3月我中心接受IVF-ET治疗采用拮抗剂或长方案的卵巢正常反应患者的临床资料,根据新鲜周期的方案及是否移植分为3组,A组:拮抗剂未移植组(128例),B组:拮抗剂移植组(138例),C组:长方案移植组(720例);同时,进一步统计拮抗剂未移植组患者第1次冷冻胚胎移植(frozen embryo transfer,FET)转化日内膜厚度及临床结局,作为D组,比较拮抗剂方案与长方案在正常反应人群中应用的临床特点及结局。结果(1)A、B组使用促性腺激素(gonadotropin,Gn)时间及用量均0.05;(4)B、C、D 3组患者生化妊娠率、临床妊娠率差异均无统计学意义,B组患者着床率最低,流产率最高,与C组间差异有统计学意义(P<0.05)。结论正常反应人群拮抗剂方案可获得与长方案相似的卵母细胞及胚胎,拮抗剂对子宫内膜容受性的负面影响可能会引起临床妊娠率低,流产率高。 Objective To analyze and compare the clinical features and outcomes of in vitro fertilization-embryo transfer(IVF-ET)cycles in normal responders using gonadotrophin(Gn)releasing hormone(GnRH)antagonist or GnRH agonist long protocol.Methods The clinical data of patients who received IVF treatment and had normal ovarian response to GnRH antagonist or GnRH agonist long protocol in our reproductive center from January 2017 to March 2019 were collected.According to the treatment protocol and the fresh embryo transplanted or not,these patients were divided into Group A(receiving GnRH antagonist,but no fresh embryo transplanted,n=128),Group B(GnRH antagonist,with fresh embryo transplanted,n=138),and Group C(GnRH agonist long protocol,with fresh embryo transplanted,n=720).Besides,the frozen embryo transfer(FET)cycles of Group A were analyzed,and served as Group D.The thickness of endometrium on luteal conversion day and outcome of Group D were compared with those of Group B and Group C.Results(1)The duration and dosage of Gn were shorter and less in Group A and B than Group C,and statistical difference was seen in Gn duration(P<0.05),and in Gn dosage only between Group A and C(P<0.05).(2)On HCG day,the serum estradiol(E2)level were lower in Group A and B than Group C(P<0.05),the endometrium of Group C was the thickest,and the thickness of endometrium on luteal conversion day of Group D was lower than that on the HCG day of Group A,B and C,where the differences between Group A and B,and Group C and D were statistically significant(P<0.05).(3)The number of oocytes obtained in Group A and B were less than that in Group C(P<0.05),but there were no statistical difference in metaphaseⅡ(MⅡ)oocyte rate,normal fertilization rate and high-quality embryo rate among Group A,B and C.(4)Biochemical pregnancy rate and clinical pregnancy rate had no statistical differences among Group B,C,and D(P<0.05).Group B had the lowest implantation rate but the highest miscarriage rate,and had obvious differences with Group C(P<0.05).Conclusion GnRH antagonist protocol can obtain similar oocytes and embryos as the GnRH-a long protocol in normal response population.However,the antagonist may exert negative impact on endometrial receptivity and result in low pregnancy rate and high abortion rate.
作者 张争 蒋承芳 李玉艳 何畏 ZHANG Zheng;JIANG Chengfang;LI Yuyan;HE Wei(Reproductive Medical Center,Department of Gynaecology and Obstetrics First Affiliated Hospital,Army Medical University(Third Military Medical University),Chongqing,400038,China)
出处 《陆军军医大学学报》 CAS CSCD 北大核心 2022年第5期484-488,共5页 Journal of Army Medical University
基金 军队计生专项研究任务(17JS002)。
关键词 拮抗剂方案 正常反应人群 体外授精-胚胎移植 GnRH antagonist protocol normal response population in vitro fertilization-embryo transfer
  • 相关文献

参考文献3

二级参考文献37

  • 1段金良,刘英,曾琼芳,蒋元华,黄雅丹.促性腺激素释放激素拮抗剂的3种用药方案在体外受精-胚胎移植中的有效性对比[J].实用妇产科杂志,2010,26(3):216-219. 被引量:5
  • 2Escudero E, Bosch E, Crespo J, et al. Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients[J]. Fertil Steril, 2004, 81 (3):562-566.
  • 3Oberye J J, Mannaerts BM, Huisman JA, et al. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers[J]. Fertil Steril, 1999, 72(6):1006-1012.
  • 4Huirne JA, Lambalk CB. Gonadotropin-releasing-hormone- receptor antagonists[J]. Laneet, 2001, 358(9295):1793-1803.
  • 5Copperman AB, Benadiva C. Optimal usage of the GnRH antagonists: a review of the literature[J]. Reprod Biol Endoerinol, 2013, 11:20.
  • 6Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology[J]. Cochrane Database Syst Rev, 2011(5):CD001750.
  • 7Qiao J, Lu G, Zhang HW, et al. A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates[J]. Gynecol Endocrinol, 2012, 28(10):800-804.
  • 8Marei R, Caserta D, Lisi F, et al. In vitro fertilizationstimulationprotocol for normal responder patients [J]. Gynecol Endocrinol, 2013, 29(2): 109-112.
  • 9Griesinger G, Diedrich K, Tarlatzis BC, et al. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis[J]. Reprod Biomed Online, 2006, 13(5): 628-638.
  • 10Pundir J, Sunkara SK, E1-Toukhy T, et al. Meta-analysis ofGnRH antagonist protocols: do they reduce the risk of OHSS in PCOS?[J]. Reprod Biomed Online, 2012, 24(1):6-22.

共引文献52

同被引文献21

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部